CARLSBAD, Calif.--(BUSINESS WIRE)--Jan. 11, 2006--SD Pharmaceuticals Inc. (SDP) today announced that it has completed a third pre-clinical efficacy study on its novel non-immunogenic formulation of docetaxel (SDP-014). SDP-014 is a proprietary lyophilized nano-emulsion that does not contain the immunogenic solubilizer polysorbate 80 which is present in the currently marketed Taxotere(R). The current study was a dose ranging trial in a xenografted nude mouse animal model of Human breast cancer (MDAMB-435). The study findings confirm dose dependant efficacy of SDP-014 that was equal or superior to the currently marketed Taxotere(R) with an improved side effect profile. Taxotere is one of the largest cancer drugs with worldwide sales approaching $2 billion per year.